8.3 Continuous Quality Improvement, Risk Management, and Inventory Control

Continuous Quality Improvement, Risk Management, and Inventory Control

Quick Answer: Pharmacy quality and risk programs apply structured improvement frameworks (PDSA, Lean, Six Sigma), rigorous medication-error analysis, and disciplined inventory control to protect patients and sustain operations. Controlled substances add DEA-specific requirements including biennial inventory and Form 106 for theft or loss.

Continuous Quality Improvement (CQI)

CQI is a structured, data-driven approach to improving processes over time. Unlike one-time fixes, CQI treats quality as an ongoing organizational commitment.

The PDSA Cycle

The Plan-Do-Study-Act (PDSA) cycle is the most widely used improvement framework.

1. Plan — define the problem, set measurable objectives, predict results, and design a small-scale test.
2. Do — implement the test on a small scale and document observations.
3. Study — compare results against predictions; analyze variation and unintended effects.
4. Act — adopt, adapt, or abandon. If successful, scale and standardize; if not, iterate with a revised plan.

Other Improvement Methodologies

• Six Sigma — uses DMAIC (Define, Measure, Analyze, Improve, Control) to reduce defects to at most 3.4 per million opportunities; emphasizes statistical control.
• Lean — focuses on eliminating waste (defects, overproduction, waiting, non-utilized talent, transportation, inventory, motion, extra-processing — the "TIMWOOD" wastes).
• Root cause analysis (RCA) — retrospective investigation after a sentinel event, asking "5 Whys" to identify systemic causes rather than blaming individuals.
• Failure Mode and Effects Analysis (FMEA) — prospective, team-based risk assessment that scores failure modes by severity × occurrence × detectability to prioritize mitigation.

Medication Error Reduction

The Institute for Safe Medication Practices (ISMP) publishes high-alert medication lists (anticoagulants, insulin, opioids, chemotherapy, concentrated electrolytes) that bear heightened risk of catastrophic harm. Prevention strategies include independent double checks, smart-pump dose libraries, tall-man lettering, and standardized order sets. Error reporting flows to MedMARX (national, anonymous) and FDA MedWatch for serious adverse events. A just culture model distinguishes human error (coachable) from at-risk behavior (coachable plus system redesign) and reckless behavior (sanction), encouraging reporting without minimizing accountability.

Risk Management

Risk management is the systematic identification, analysis, and mitigation of exposures. Pharmacy risks include medication errors, malpractice and professional liability (covered by professional liability insurance), privacy breaches under HIPAA, and financial fraud. Incident reporting — internal forms capturing near-misses and actual events — feeds CQI. Sentinel events trigger RCA and often a report to The Joint Commission. The pharmacist-in-charge maintains liability coverage and ensures protocol-driven delegation to technicians within state scope.

Procurement and Inventory Control

Procurement

Most pharmacies purchase through wholesale distributors under a prime vendor agreement (PVA) that offers volume discounts and predictable delivery in exchange for approximately 80% of purchases. Group purchasing organizations (GPOs) aggregate buying power across members to negotiate manufacturer rebates. Pharmacies must verify wholesalers are licensed and maintain pedigree documentation per the Drug Supply Chain Security Act (DSCSA).

Inventory Control

• ABC analysis — classifies inventory by cost: A (top 20% of SKUs, 70 to 80% of spend), B (next 30%), C (bottom 50%). A-items receive tight control; C-items looser.
• Reorder point = (average daily usage × lead time) + safety stock.
• Turnover rate = cost of goods sold divided by average inventory; healthy turnover is approximately 12 times per year.
• Drug shortages — managed via ASHP guidelines: identify therapeutic alternatives, conserve supply, communicate with prescribers, and avoid hoarding.

Controlled Substances

DEA registrants must maintain a biennial inventory (every 2 years, on any date the registrant selects) of all Schedule II to V substances, recorded without witness for Schedules III to V and with a witness for Schedule II. Dispensing records (DEA Form 222 for Schedule II transfers; order records for III to V) are retained for 2 years. Theft, loss, or significant diversion must be reported to DEA on Form 106 within one business day of discovery and to the state board per local rules.

Expiration, Recalls, and Storage

• Expiration date management — first-expire-first-out (FEFO) stocking; quarterly scans to remove short-dated stock.
• Recalls — Class I (reasonable probability of serious adverse health consequences or death), Class II (temporary or medically reversible adverse health consequences), Class III (not likely to cause adverse health consequences). Pharmacies follow manufacturer or FDA instructions for return or disposal and document patient notification when dispensed product is affected.
• Storage requirements — USP General Chapter <659> defines controlled room temperature (20 to 25°C, excursions 15 to 30°C), refrigeration (2 to 8°C), and freezing (-25 to -10°C). Daily temperature logs are standard practice.

Pharmacy Compounding Quality Assurance

USP <795> (nonsterile), <797> (sterile), and <800> (hazardous drugs) define quality standards for ingredients, environment, personnel competency, and beyond-use dating. <797> requires ISO-classified cleanroom suites, environmental monitoring, and gloved fingertip sampling. <800> mandates containment primary engineering controls (C-PEC) and containment secondary engineering controls (C-SEC) for hazardous drug handling to protect personnel and patients.